About Transition
----------------
Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally or developed internally using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit http://www.transitiontherapeutics.com.
Extracts of the Financial Statements to Follow:
CONSOLIDATED BALANCE SHEETS
(Unaudited)
September 30, June 30,
2008 2008
$ $
-------------------------------------------------------------------------
ASSETS
Current
Cash and cash equivalents 26,885,506 22,952,865
Held-to-maturity investments 31,213,216 40,710,765
SCT receivable 1,650,000 1,650,000
Due from Eli Lilly and Company 1,913,505 472,220
GST receivable 325,376 278,784
Investment tax credits receivable 795,161 693,057
Prepaid expenses and deposits 638,811 974,426
---------------------
'/>"/>
| SOURCE Transition Therapeutics Inc. Copyright©2008 PR Newswire. All rights reserved |